About Us

Kent Thoelke is a pioneering healthcare executive with over 30 years of clinical research experience. As CEO of Paradigm Health, he leads the company's mission to create equitable access to superior healthcare for patients worldwide. Prior to joining Paradigm Health, Kent served as Chief Innovation Officer at ICON plc following its acquisition of PRA Health Sciences, where he was Chief Scientific Officer. Throughout his career at these organizations, he has driven digital transformation in clinical trials and championed data-driven approaches to make drug development more efficient and equitable across multiple therapeutic areas and geographic regions.

Jonathan Hirsch is a strategic healthcare leader and serial entrepreneur with extensive experience in clinical research innovation. As Chief Strategy and Growth Officer at Paradigm Health, he drives initiatives to democratize clinical trials and create equitable access to advanced healthcare options for patients worldwide. Prior to joining Paradigm Health, Jonathan served as Co-Founder and Chair of the Advisory Board at Synapticure Inc., while maintaining active investment and advisory roles in pioneering healthcare companies including Arbital Health, Frame, and Thyme Care. Jonathan holds an M.Sci. in Biological Sciences with a specialization in Neuroscience from Stanford University and an A.B. in Biology and Political Science from the University of Chicago.

Jay Trepanier is a strategic financial executive with over 30 years of experience in corporate financial operations and business leadership. As Chief Financial Officer at Paradigm Health, he oversees the company's financial strategy and operations, leveraging his extensive experience in private equity and venture capital environments. Prior to Paradigm Health, Jay served as Senior Vice President of FP&A, Global Proposals, and Vendor Management at PRA Health Sciences, Chief Finance and Operations Officer at Science 37, and CEO of Clinverse Inc. Throughout his career, he has successfully led capital raises exceeding $200M and orchestrated eight M&A transactions ranging from $2M to $12B in total value. Jay holds a BS in Business from the University of New Hampshire Peter T. Paul College of Business and Economics, a BS in Accounting from West Virginia University, and is a Certified Public Accountant.

Elijah Meerson is an accomplished technology leader with extensive experience building innovative software solutions in healthcare and real estate. As Chief Technology Officer at Paradigm Health, he leads the development of next-generation platforms to optimize clinical research accessibility and efficiency. Prior to Paradigm Health, Elijah served as CTO at Orchard and VP of Engineering at Flatiron Health, where he demonstrated his expertise in scaling engineering teams and delivering transformative technology solutions. He continues to contribute to the technology ecosystem as an advisor to companies including Muru Inc. Elijah holds a B.S. in Computer Science from Georgetown University.

Michelle Lee is a strategic and versatile leader with over 25 years of experience driving operational efficiencies and transformative business strategies across healthcare and technology sectors. As Chief Operating Officer at Paradigm Health, she is responsible for the day to day operations of the business and oversees a broad portfolio of sponsor, provider, and internal facing functions. Prior to joining Paradigm Health, Michelle served as Chief Operating Officer at Vori Health, and has held leadership positions at Honor, Lyric, and McKesson Technology. Michelle holds a B.A from Harvard University and an MBA in Healthcare Management from Wharton.

Dr. Paul Kluetz is a medical oncologist who has published over 150 peer-reviewed manuscripts and remains clinically active, caring for patients and supervising medical residents as a teaching attending at Georgetown University Hospital. As Chief Medical Officer at Paradigm Health, Dr. Kluetz helps advance Paradigm Health’s technology platform focused on improving clinical trial access for all patients through innovative approaches to optimize trial screening, accrual, and efficient conduct. Prior to Paradigm Health, Dr. Kluetz served as Deputy Director of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). During his tenure at FDA, Dr. Kluetz founded and led several initiatives including the OCE’s patient-focused drug development program, real-world evidence program, and trial modernization efforts including pragmatic and decentralized trial designs.